US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lisata Therapeutics, Inc. - Common Stock
(NQ:
LSTA
)
1.470
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lisata Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
September 28, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in InfoSec World 2023
September 20, 2023
Gregory Berkin, Chief Information Officer of Lisata, to participate in keynote discussion on CISO leadership and managing the risks of artificial intelligence
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors
September 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
September 06, 2023
Independent Data Safety Monitoring Committee recommends study continuation (criteria for futility not met)
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in September
September 05, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 14, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For August 14, 2023
↗
August 14, 2023
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.
Via
Benzinga
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma
August 08, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time
August 07, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
July 11, 2023
Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference
June 12, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1
May 24, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time
May 02, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in May
April 27, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
April 20, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
April 18, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 30, 2023
Conference call scheduled for today at 4:30 p.m. Eastern time
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 30, 2023
↗
March 30, 2023
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.
Via
Benzinga
Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
March 23, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
March 10, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
March 07, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Lisata Therapeutics to Webcast Live at the Life Sciences Investor Forum on March 9th
March 06, 2023
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Lisata Therapeutics Announces Participation in Upcoming Conferences in February
February 01, 2023
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
↗
December 13, 2022
On Tuesday, 49 companies hit new 52-week lows.
Via
Benzinga
Lisata Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 10, 2022
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
↗
December 23, 2022
OnFriday, 143 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Wednesday
↗
December 14, 2022
On Wednesday, 115 stocks hit new 52-week lows.
Via
Benzinga
Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022
November 07, 2022
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
Lisata Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on Thursday, November 10, 2022, at 4:30 p.m. Eastern Time
November 03, 2022
From
Lisata Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
